Journal of Alzheimer’s Disease 39 (2014) 661–668 DOI 10.3233/JAD-131265 IOS Press

661

Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts Eileen M. Moorea,b,∗ , David Amesa,c , Alastair G. Manderb , Ross P. Carneb,d , Henry Brodatye,f , Michael C. Woodwardg , Karyn Boundyh , Kathryn A. Ellisa,c,i , Ashley I. Bushi,j , Noel G. Fauxi , Ralph N. Martinsk,l , Colin L. Mastersi,m , Christopher C. Rowen , Cassandra Szoekec,o and David A. Wattersb,d a Department

of Psychiatry, The University of Melbourne, Parkville, VIC, Australia Health, Geelong, VIC, Australia c National Ageing Research Institute, Parkville, VIC, Australia d Deakin University, School of Medicine, Waurn Ponds, VIC, Australia e The University of New South Wales, Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre, Sydney, NSW, Australia f Aged Care Psychiatry, Prince of Wales Hospital, Randwick, NSW, Australia g Austin Health, Heidelberg Repatriation Hospital, Heidelberg, VIC, Australia h The Queen Elizabeth Hospital, Woodville South, SA, Australia i The University of Melbourne, Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia j Department of Pathology, The University of Melbourne, Parkville, VIC, Australia k Edith Cowan University, Centre of Excellence for Alzheimer’s Disease Research & Care, School of Exercise, Biomedical and Health Sciences, Joondalup, WA, Australia l Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital), Neurosciences Unit, Health Department of Western Australia, Perth, WA, Australia m The University of Melbourne, Centre for Neuroscience, Parkville, VIC, Australia n Austin PET centre, Austin Hospital, Heidelberg, VIC, Australia o Preventative Health Flagship, Commonwealth Science Industry Research Organization, Parkville, VIC, Australia b Barwon

Accepted 2 October 2013

Abstract. Background: Folate fortification of food aims to reduce the number of babies born with neural tube defects, but has been associated with cognitive impairment when vitamin B12 levels are deficient. Given the prevalence of low vitamin B12 levels among the elderly, and the global deployment of food fortification programs, investigation of the associations between cognitive impairment, vitamin B12, and folate are needed. Objective: To investigate the associations of serum vitamin B12, red cell folate, and cognitive impairment. ∗ Correspondence

to: Dr. Eileen Moore, CNR Bellarine and Ryrie Street, PO Box 281, Level 4, Douglas Hocking Research Institute, The Geelong Hospital, Geelong, VIC 3220, Australia. Tel.: +61 420693726; Fax: +61 342152023; E-mails: dr.eileenmoore@ gmail.com; [email protected].

ISSN 1387-2877/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved

662

E.M. Moore et al. / Folic Acid, Vitamin B12, and Cognition

Methods: Data were collected on 1,354 subjects in two studies investigating cognitive impairment, and from patients attending for assessment or management of memory problems in the Barwon region of south eastern Australia between 2001 and 2011. Eligible subjects who had blood measurements of vitamin B12 and red cell folate taken within six months of cognitive testing were included. Subjects with stroke or neurodegenerative diseases other than Alzheimer’s disease were excluded. A Mini-Mental State Examination score of 45.3 nmol/L) was reported to increase from 7% before 1994 to 38% in 1999 in over-60 year olds [9] in a study that compared levels before and after food fortification in the US. Two large studies from the US; namely, the NHANES [6] and the Framingham Heart Study [10], reported that high folate or folic acid supplementation may exacerbate cognitive impairment associated with low serum vitamin B12 levels. The NHANES study investigated cognitive impairment and vitamin B12 levels in 1,301 community-

E.M. Moore et al. / Folic Acid, Vitamin B12, and Cognition

dwelling volunteers aged 60 years and older. Participants with low serum vitamin B12 levels (59 nmol/L) had higher levels of Hcy and MMA, and were four times more likely to experience cognitive impairment (odds ratio 4.3, 95% confidence interval (CI): 2.3–8.0) than individuals with normal levels of vitamin B12 and folate [6]. Vitamin B12 deficiency is common in older adults: 6.1% of over-65 year old Finns [11], 7.8% of Israelis [12], 15.3% of Canadians [13], and 23.8% of 74–80 year old Dutch people [14]. Given the global scale of deployment of food fortification programs, and the prevalence of vitamin B12 deficiency among older adults, the effect on cognition of high folate or folic acid supplementation merits immediate investigation. Previous studies have investigated serum folate or folic acid; whereas our aim was to investigate the associations of red cell folate, serum vitamin B12, and cognitive impairment in a large cohort from the Australian population. METHODS Participants and settings Vitamin B12, folate, and cognitive test scores were examined for 1,354 participants. Blood samples for biochemical markers were taken within six months of cognitive testing. Participants were recruited from two large studies examining cognition in late life, namely the Prospective Research in Memory (PRIME) clinics study and the AIBL study. The PRIME study recruited 970 participants from nine sites in Australia, including three each in Victoria and New South Wales, and one each in Queensland, Western Australia, and South Australia. The AIBL study recruited 1,112 participants in Victoria (60%) and Western Australia (40%). The study cohorts and methods of the PRIME study and the AIBL study are described elsewhere [15, 16]. Additional participants who resided in the Barwon region of south east Australia between 2001 and 2011 were recruited through the local Cognitive, Dementia and Memory Services (CDAMS), and a geriatrician’s private practice. Most (83%) of the blood samples were taken between 2001 and September 2009; well after the introduction of voluntary fortification of foods with folic acid in Australia in 1995. The remainder was taken after the introduction of mandatory fortification in September 2009. A survey of Australians aged 27–77

663

years reported that mean serum folate levels increased by 38% in the years after voluntary food fortification was introduced [17]. Serum folate levels of the sample studied varied with the consumption of foods fortified with folic acid, but not with age or gender. Study design PRIME study subjects were recruited during routine patient care at nine memory clinics and included people with AD (National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders NINCDS-ADRDA criteria) and individuals with mild cognitive impairment (MCI, Petersen criteria). The aim of the PRIME study was to assess the clinical outcomes of patients with dementia at memory clinics across Australia. Participants were assessed at baseline and then after 3, 6, 12, 24, and 36 months. At each visit, participants underwent assessment by a neuropsychological battery for cognition, and participants’ primary caregivers completed Zarit burden interviews. AIBL study subjects volunteered after promotion of the study on television in late 2006, or were referred to the study by the clinician treating them for a memory problem, and included people aged over-60 years with normal cognition, MCI, or AD. The aim of the AIBL study was to investigate the markers that predict future AD. Participants were allocated to one of three diagnostic groups by clinical panel review. Participants of the AIBL study underwent a neuropsychological battery assessing the domains of cognition that are affected in AD and other dementias. Assessment was at baseline and then after 18 months. Eligible participants assessed at the Barwon region CDAMS or geriatrician’s private practice for memory complaints were recruited at a routine visit. Eligible subjects had a Mini-Mental State Examination (MMSE) score performed within six months of blood being drawn. Participants with diagnoses of stroke or neurodegenerative diseases other than AD were excluded. Biochemical measurements The lower reference value for serum vitamin B12 varies with the assay used, but approximates to 150 pmol/L. Megaloblastic anemia and sub-acute combined degeneration of the spinal cord occurs with serum vitamin B12 levels below this cut-off. A subclinical low-normal range (∼150–250 pmol/L) has been widely investigated [18]. Carmel et al. identified that metabolic abnormalities can occur (such as elevated

664

E.M. Moore et al. / Folic Acid, Vitamin B12, and Cognition

homocysteine or methylmalonic acid levels, or altered deoxyuridine suppression) when vitamin B12 levels are in the subclinical low-normal range, without immediate neurological or hematological signs [19]. Serum vitamin B12 levels 1,594 nmol/L) were considered ‘high’, whereas RCF levels of 1,594 nmol/L or lower were considered ‘normal’. These cut-offs for biochemical marker status approximate those used by the Framingham Heart Study investigators [10]. Serum vitamin B12 and RCF levels were measured using the ADVIA Centaur chemiluminescent microparticle immunoassay at most sites. Exceptions were as follows: Prime Site 2 used the Tosoh immunoassay analyser AIA600, Prime Site 4 used the Roche Cobas 8000 electrochemiluminescence immunoassay, and Prime Site 6 used a Siemens Healthcare Diagnostic Immulite 2000 immunoassay.

Ethical approval Institutional review was performed at each study host site. Reviewing committees included the Barwon Health Human Research Ethics Committee (HREC, Victoria), Austin Health HREC (Victoria), St Vincent’s Hospital Governance Review Unit (Victoria), Hunter New England HREC (New South Wales), Northern Hospital Network HREC (New South Wales), Northern Sydney Central Coast HREC (New South Wales), Metro North Health Service District HREC (Queensland), South Metropolitan Area Health Service HREC (Western Australia), and The Queen Elizabeth Hospital Ethics of Human Research Committee (South Australia). Statistical analyses A binary logistic regression model was formed with cognitive performance as the response variable. Participants who scored below 24 on the MMSE were considered to have impaired cognitive performance. The MMSE is sensitive to age, level of education,

Fig. 1. Recruitment, inclusion and exclusion of the study cohort. PRIME study, Prospective Research in MEmory clinics study; AIBL, Australian Imaging, Biomarkers and Lifestyle study of ageing; CDAMS, Cognitive, Dementia and Memory Services memory clinic; AD, Alzheimer’s disease; MCI, Mild cognitive impairment; MMSE, Mini-Mental State Examination.

E.M. Moore et al. / Folic Acid, Vitamin B12, and Cognition

and depression, so the model was adjusted for these variables. Level of education was classified as ‘primary’ (less than six years of schooling), ‘secondary’ (between six and thirteen years of schooling), and ‘tertiary’ (more than 13 years of schooling). The reference category for level of education was ‘primary’. Participants were classified as having a history of depression if depression or depressive symptoms were noted in their patient medical history. Four categories for biochemical status were formed: namely, category (A) normal vitamin B12 and RCF, category (B) normal vitamin B12 and high RCF, category (C) low vitamin B12 and normal RCF, and category (D) low vitamin B12 and high RCF. The reference level for biochemical status used was category (A). The grouping and analyses technique used in this study is similar to that first described by Selhub and colleagues [6], and later used by Miller and colleagues [21]. MMSE scores and biochemical measurements were examined for 480 patients with AD, 187 with MCI, and 687 participants who were cognitively-intact. Participants were recruited during two controlled studies: (1) the PRIME clinics study (n = 970), and (2) the AIBL study (n = 1,112). An additional 1,797 patients treated for memory complaints in the Barwon region of south eastern Australia were also screened. There were 532 participants that were recruited from more than one source; their data were merged. Figure 1 describes recruitment, inclusion, and exclusion of participants forming the study cohort.

RESULTS The characteristics of the study cohort are shown in Table 1. Participants with low vitamin B12 levels (1,594 nmol/L) were older, and a greater proportion had a diagnosis of AD, than participants with biochemical measurements within the normal ranges. Both of the groups with high RCF (groups B and D) had a much higher proportion of folic acid supplement users (15% and 23%, respectively). Participants with low serum vitamin B12 levels (1,594 nmol/L) were more likely to have an impaired cognitive performance (MMSE 1,594 nmol/L) were also at increased risk for cognitive impairment (AOR 1.74, 95% CI: 1.03–2.95). This important new finding suggests that high folate levels may be an independent risk factor for cognitive impairment. Folic acid given in supplements and fortified foods may inhibit the shared biochemical pathway between folate and vitamin B12, leading to accumulation of homocysteine or to lowered methylation potential. This possible disease mechanism was suggested by Selhub et al. [22], and later by Faux et al. [8], in which high homocysteine was associated with both high or low folate levels. Evidence from the NHANES [23] and Framingham cohort [10] studies suggest that it is unmetabolized folic acid that is associated with poor cognitive function. In the former study, higher levels of 5-methyltetrahydrofolate were associated with better cognition, whereas higher folic acid was associated with poorer cognitive function. Both of the groups with the highest proportion of folic acid supplement users showed the greatest risk of cognitive impairment, so our data are consistent with the idea that high levels of folic acid may be detrimental to cognitive function. Frequently, clinicians have advised patients in the early stages of cognitive decline to take extra folate on the basis of early work reporting less dementia with high folate intake [24], so this is a possible source of confounding in observational studies that show association between high folate levels and poor

666

E.M. Moore et al. / Folic Acid, Vitamin B12, and Cognition Table 1 Characteristics of cohort

Characteristic

Biochemical status

Vitamin B12 Red cell folate Total number, n Age, mean (SD) Males, n (%) Tertiary education, n (%) Depression, n (%) MMSE score, mean (SD) Diagnosis: AD, n (%) MCI, n (%)a Cognitively-intact, n (%)b B12 supplement users, n (%) Folate supplement users, n (%) a Mild

Difference

(A)

(B)

(C)

(D)

p

≥250 pmol/L ≤1,594 nmol/L 742 72.7 (8.4) 287 (38.7%) 301 (40.6%) 210 (28.3%) 26.2 (4.6) 215 (29.0%) 99 (13.3%) 428 (57.7%) 81 (10.9%) 21 (2.8%)

≥250 pmol/L >1,594 nmol/L 97 74.9 (7.7) 33 (34.0%) 37 (38.1%) 35 (36.1%) 25.2 (4.7) 36 (37.1%) 19 (19.6%) 42 (43.3%) 19 (19.6%) 15 (15.5%)

Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts.

Folate fortification of food aims to reduce the number of babies born with neural tube defects, but has been associated with cognitive impairment when...
301KB Sizes 0 Downloads 0 Views